Paul Roepman
YOU?
Author Swipe
View article: Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol
Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol Open
BRCA1/2 are crucial in the homologous recombination repair (HRR) pathway, with loss‐of‐function (LoF) alterations predicting sensitivity to PARP‐inhibitors (PARPi). Whether other HRR‐gene alterations confer PARPi sensitivity remains unclea…
View article: Clinical application of tumour whole genome sequencing in routine molecular diagnostics for solid cancer patients
Clinical application of tumour whole genome sequencing in routine molecular diagnostics for solid cancer patients Open
Molecular testing is increasingly relevant for enabling precision medicine for cancer patients. Whole genome sequencing (WGS) provides a tumour-agnostic solution for the growing complexity of DNA-based biomarker detection, with promising r…
View article: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)
The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP) Open
In our population, PAL emerged as a pan-cancer determinant of outcome to TT. Our findings support refined patient selection for TT and highlight the rationale for combinatorial treatment strategies in patients with multiple affected pathwa…
View article: Table S4. Differential expression4 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol
Table S4. Differential expression4 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Open
Results of the differential expression analysis.
View article: Table S1. Response associations1 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol
Table S1. Response associations1 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Open
Baseline characteristics of all patients that completed at least one treatment cycle, stratified by objective response. Percentages may not total 100 due to rounding. Annotations: * Two patients with non-small cell lung cancer not otherwis…
View article: Table S6. Other c-MET-inhibitors6 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol
Table S6. Other c-MET-inhibitors6 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Open
Study characteristics and efficacy outcomes of trials with selective type 1b c-MET-inhibitors in MET mutated NSCLC. Abbreviations: ECOG, Eastern Cooperative Oncology Group; ORR, objective response rate; CI, confidence interval; mDoR, media…
View article: Table S5. Other crizotinib trials5 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol
Table S5. Other crizotinib trials5 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Open
Study characteristics and efficacy outcomes of trials with crizotinib in MET mutated NSCLC. Abbreviations: ECOG, Eastern Cooperative Oncology Group; ORR, objective response rate; CI, confidence interval; mDoR, median duration of response; …
View article: Table S3. Met alterations3 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol
Table S3. Met alterations3 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Open
Type of Met alterations found by both inclusion diagnostics and WGS. Variants annotated according to the NM_000245 (MANE transcript). Abbreviations: NGS, next generation sequencing; PCR, polymerase chain reaction; WGS, whole genome sequenc…
View article: Figure S1. Accrual and follow-up1 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol
Figure S1. Accrual and follow-up1 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Open
Flowchart of the accrual and follow-up of the cohort. Abbreviations: NSCLC, non small cell lung cancer.
View article: Table S7. Representativeness7 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol
Table S7. Representativeness7 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Open
Representativeness of the participants included in the current study for the general population.
View article: Table S2. First progression sites2 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol
Table S2. First progression sites2 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Open
Site or type of first progression of all patients that started crizotinib treatment. * Multiple sites include: bone and lymph node; bone, heart and lung; bone, lung and pleura; brain and lung; lung and bone; lung and thyroid gland.
View article: Data from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol
Data from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Open
Purpose: To provide patients with MET-mutated advanced non–small cell lung cancer (METmut aNSCLC) access to crizotinib, further substantiate evidence of its efficacy and safety in this setting, and find potential biomarkers f…
View article: Supplementary Table S2 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
Supplementary Table S2 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol Open
Supplementary Table S2. Inclusion and exclusion criteria.
View article: Supplementary Table S5 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
Supplementary Table S5 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol Open
Supplementary Table S5. Baseline characteristics and clinical outcome data of melanoma cohort.
View article: Data from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
Data from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol Open
Purpose:The treatment efficacy of nivolumab was evaluated in patients with advanced, treatment-refractory solid mismatch repair deficiency/microsatellite-instable (dMMR/MSI) tumors, and in-depth biomarker analyses were performed to inform …
View article: Supplementary Figure S3 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
Supplementary Figure S3 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol Open
Supplementary Figure S3. Association between immune marker gene expression and clinical benefit to ICB.
View article: Supplementary Figure S1 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
Supplementary Figure S1 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol Open
Supplementary Figure S1. Accrual flowchart including reasons for ineligibility.
View article: Supplementary Table S3 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
Supplementary Table S3 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol Open
Supplementary Table S3. Baseline characteristics and clinical outcome data of evaluable dMMR/MSI patients treated with nivolumab in high tumor mutational load cohort.
View article: Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Open
Purpose: To provide patients with MET-mutated advanced non–small cell lung cancer (METmut aNSCLC) access to crizotinib, further substantiate evidence of its efficacy and safety in this setting, and find potential biomarkers for nonresponse…
View article: Supplementary Table S4 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
Supplementary Table S4 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol Open
Supplementary Table S4. Evaluated immune marker gene sets.
View article: Supplementary Table S8 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
Supplementary Table S8 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol Open
Supplementary Table S8. Overview per patient included in biomarker analysis.
View article: Supplementary Table S6 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
Supplementary Table S6 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol Open
Supplementary Table S6. Baseline characteristics of all included patients, regardless of evaluability according to protocol definition.
View article: Supplementary Table S7 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
Supplementary Table S7 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol Open
Supplementary Table S7. Best overall response for all evaluable patients at the time of data cut-off.
View article: Supplementary Table S1 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
Supplementary Table S1 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol Open
Supplementary Table S1. Representativeness of study participants.
View article: Supplementary Figure S2 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
Supplementary Figure S2 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol Open
Supplementary Figure S2. Genomic biomarkers of clinical benefit to ICB.
View article: Table S1 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Table S1 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Table S1. Overview per patient.
View article: Table S2 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Table S2 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Table S2. Evaluated marker gene sets.
View article: Data from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Data from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Purpose:To evaluate the efficacy of pembrolizumab across multiple cancer types harboring different levels of whole-genome sequencing–based tumor mutational load (TML; total of nonsynonymous mutations across the genome) in patients included…
View article: Figure S4 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Figure S4 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Figure S4. Mutational landscape stratified by cohort.
View article: Figure S3 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Figure S3 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Figure S3. Correlation between TML and TMB.